Growth Metrics

Omeros (OMER) Gross Margin (2014 - 2026)

Omeros recorded quarterly Gross Margin of 94.07% in Q1 2026, down 4.88% quarter-over-quarter from 98.89% in Q3 2021.

Omeros' Gross Margin history runs 9 years deep, the most recent figure standing at 94.07% for Q1 2026.

  • In Q1 2026, Gross Margin changed N/A year-over-year to 94.07%; the TTM figure through Mar 2026 stood at 98.16% (down 66.0% YoY), while the FY2020 annual figure was 98.78%, down 45.0% from the prior year.
  • Gross Margin came in at 94.07% for Q1 2026 at Omeros, down from 98.89% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 94.07% in Q1 2026 to a low of 94.07% in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 79.04%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 86.85%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 91.79%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 82.22%
10 Omeros 772.03 Mn 636.71 Mn 9.31 Mn 94.07%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 94.07%
Sep 30, 2021 98.89%
Jun 30, 2021 98.81%
Mar 31, 2021 98.75%
Dec 31, 2020 99.18%
Sep 30, 2020 98.46%
Jun 30, 2020 98.91%
Mar 31, 2020 98.87%
Dec 31, 2019 98.80%
Sep 30, 2019 99.07%
Jun 30, 2019 99.79%
Mar 31, 2019 99.40%
Dec 31, 2018 99.29%
Sep 30, 2018 99.22%
Jun 30, 2018 92.99%
Mar 31, 2018 87.22%
Dec 31, 2017 96.62%
Sep 30, 2017 99.15%
Jun 30, 2017 99.08%
Mar 31, 2017 97.79%
Dec 31, 2016 97.06%
Sep 30, 2016 96.65%
Jun 30, 2016 96.73%
Mar 31, 2016 95.59%
Dec 31, 2015 93.75%
Sep 30, 2015 92.39%
Jun 30, 2015 88.55%
Mar 31, 2015 97.16%
Dec 31, 2014 100.00%
Sep 30, 2014 100.00%
Jun 30, 2014 100.00%
Mar 31, 2014 100.00%